Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Little Green PharmaASX:LGP -4.00% Equity-to-Asset is 0.89 as of Mar. 2026, which is 1% above its 10-year median of 0.88. The stock has 3 warning signs investors should review. Among 1,006 Drug Manufacturers companies, Little Green Pharma ranks better than 92.94% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Little Green Pharma's Total Stockholders Equity for the quarter that ended in Mar. 2026 was A$83.03 Mil. Little Green Pharma's Total Assets for the quarter that ended in Mar. 2026 was A$93.76 Mil.
Therefore, Little Green Pharma's Equity to Asset Ratio for the quarter that ended in Mar. 2026 was 0.89.
The historical rank and industry rank for Little Green Pharma's Equity-to-Asset or its related term are showing as below:
ASX:LGP'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.74 Med: 0.88 Max: 0.9
Current: 0.89
During the past 7 years, the highest Equity to Asset Ratio of Little Green Pharma was 0.90. The lowest was 0.74. And the median was 0.88.
ASX:LGP's Equity-to-Asset is ranked better than 92.94% of 1006
companies
in the Drug Manufacturers industry
Industry Median: 0.61
vs ASX:LGP: 0.89
Little Green Pharma (ASX:LGP) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Little Green Pharma Equity-to-Asset Related Terms
Little Green Pharma Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Little Green Pharma's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Little Green Pharma's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Little Green Pharma Equity-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Little Green Pharma's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Little Green Pharma's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Little Green Pharma's Equity to Asset Ratio for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Little Green Pharma (ASX:LGP) has a Equity-to-Asset of 0.89 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Little Green Pharma and its competitors. This is near median its historical median of 0.88. Over the past decade, Little Green Pharma's Equity-to-Asset has ranged from 0.74 to 0.90. According to the industry distribution chart, Little Green Pharma ranks #71 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 7.1%.
Is Little Green Pharma's Equity-to-Asset too high?
Little Green Pharma's current Equity-to-Asset of 0.89 is near median its 10-year median of 0.88. Over the past 10 years, this metric has ranged from a low of 0.74 to a high of 0.90. The Drug Manufacturers industry median Equity-to-Asset is 0.61. Little Green Pharma's value of 0.89 is 45.9% above this industry median. Based on the distribution chart, Little Green Pharma ranks #71 out of 1006 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does Little Green Pharma's Equity-to-Asset compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Little Green Pharma ranks #71 out of 1006 companies for Equity-to-Asset. This places Little Green Pharma in the top 7% of its industry — outperforming the majority of peers. The industry median Equity-to-Asset is 0.61. Little Green Pharma's value of 0.89 is 45.9% above this benchmark. Historically, Little Green Pharma's own Equity-to-Asset has ranged from 0.74 to 0.90 over the past decade. While the company's 10-year median is 0.88 vs. the industry median of 0.61, Little Green Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.61, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Little Green Pharma's current Equity-to-Asset of 0.89 is 45.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Little Green Pharma and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Little Green Pharma's current Equity-to-Asset is 0.89, which is near median its own 10-year median of 0.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Little Green Pharma stock overvalued right now?
Based on GuruFocus' analysis, Little Green Pharma (ASX:LGP) is currently considered Significantly Undervalued. The stock's GF Value™ is A$0.18, compared to a current price of A$0.07 — trading 60% below its estimated fair value. The current Equity-to-Asset is 0.89, which is near median its 10-year median of 0.88 and 45.9% above the Drug Manufacturers industry median of 0.61. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Little Green Pharma (ASX:LGP), the current Equity-to-Asset is 0.89 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Little Green Pharma Ltd is engaged in the vertically integrated medicinal cannabis business. The business activities of the company include cultivation, production, research and development, manufacturing, and distribution of medicinal cannabis products. The company's two key types of products available at Little Green Pharma are oils (which are ingested) and flowers (which are usually inhaled through vaporizing). It offers LGP-branded medicinal cannabis oil products in the Australian and European markets. The Group is organized into two operating segments: Australia and Europe (cultivation, production and distribution of cannabis products to Australian and European customers).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:LGP has been successfully added to your 
